Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 10/20 | 0.48 |
| ▸ | TGM2 | P21980 | 10/20 | 0.48 |
| ▸ | TGM1 | P22735 | 10/20 | 0.48 |
| ▸ | DDIT3 | P35638 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14054344 | 0.83 | TGM2 (0.56) | F13A1TGM2TGM1 | |
| SCHEMBL14057106 | 0.82 | TGM2 (0.42) | F13A1TGM2TGM1KMT2A | |
| SCHEMBL14057010 | 0.82 | MMP2 (0.47) | F13A1TGM2TGM1MEN1KMT2A | |
| SCHEMBL14054380 | 0.81 | TGM2 (0.54) | F13A1TGM2TGM1 | |
| SCHEMBL14055655 | 0.81 | TGM2 (0.57) | F13A1TGM2TGM1ALDH1A1 | |
| SCHEMBL14057451 | 0.81 | ALDH1A1 (0.51) | F13A1TGM2TGM1ALDH1A1MEN1 | |
| SCHEMBL14056432 | 0.81 | TGM2 (0.47) | F13A1TGM2TGM1 | |
| SCHEMBL14056641 | 0.81 | TGM2 (0.53) | F13A1TGM2TGM1 | |
| SCHEMBL14055913 | 0.80 | TGM2 (0.45) | F13A1TGM2TGM1DDIT3MEN1 | |
| SCHEMBL14057927 | 0.80 | ALDH1A1 (0.53) | F13A1TGM2TGM1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | F13A1 1540/4885TGM2 2/4885TGM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.